FY2025 EPS Estimate for Palisade Bio Boosted by Analyst

Palisade Bio, Inc. (NASDAQ:PALI) – Equities research analysts at Brookline Capital Management upped their FY2025 earnings per share estimates for Palisade Bio in a note issued to investors on Tuesday, April 8th. Brookline Capital Management analyst K. Raja now forecasts that the company will earn ($1.64) per share for the year, up from their previous estimate of ($1.86). The consensus estimate for Palisade Bio’s current full-year earnings is ($12.43) per share. Brookline Capital Management also issued estimates for Palisade Bio’s FY2026 earnings at ($0.61) EPS, FY2027 earnings at ($0.60) EPS and FY2028 earnings at ($0.57) EPS.

Palisade Bio Trading Up 2.5 %

NASDAQ PALI opened at $0.70 on Friday. The firm has a market capitalization of $3.06 million, a P/E ratio of -0.05 and a beta of 1.50. The firm’s fifty day moving average price is $0.86 and its two-hundred day moving average price is $1.86. Palisade Bio has a 1 year low of $0.60 and a 1 year high of $9.65.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($2.39) by $1.70.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Palisade Bio stock. JPMorgan Chase & Co. purchased a new position in shares of Palisade Bio, Inc. (NASDAQ:PALI) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 8,200 shares of the company’s stock, valued at approximately $29,000. JPMorgan Chase & Co. owned 0.54% of Palisade Bio as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.